Netherlands Cancer Institute Apr 15 2026 The largest published prospective evaluation of off-label targeted cancer therapies has shown that more patients could benefit from existing drugs. After including over 1600 patients in the Dutch multicenter DRUP trial, the team publishes the results in  Nature today. "Our findings underscore the fact that effective off-label use is possible, but should only be done within clinical trial settings." The pan-cancer DRUP trial seeks to realize more